HU-345 (Cannabinolquinone, CBNQ) is a drug that is able to inhibit aortic ring angiogenesis more potently than the parent compound cannabinol (CBN).[1][2] It exhibits no psychoactive effects.[citation needed]

HU-345 is made via the oxidation of CBN or THC.[3]

See also

References

  1. ↑ Kogan NM, Blázquez C, Alvarez L, Gallily R, Schlesinger M, Guzmán M, Mechoulam R (July 2006). "A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells". Molecular Pharmacology. 70 (1): 51–59. doi:10.1124/mol.105.021089. PMID 16571653. S2CID 4830577.
  2. ↑ US patent 0092584, Mechoulam R, Kogan NM, Rabinowitz R, Schlesinger M, "Therapeutic Use of Quinonoid Derivatives of Cannabinoids", granted 2011-04-21
  3. ↑ Kogan NM, Peters M, Mechoulam R (March 2021). "Cannabinoid Quinones-A Review and Novel Observations". Molecules. 26 (6): 1761. doi:10.3390/molecules26061761. PMC 8003933. PMID 33801057.
source: https://en.wikipedia.org/wiki/HU-345